JOHN P BRANCACCIO
CIK 1276551 · Chairman · last filed 2026-07-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$145.6K
Companies
10
Total Filings
67
Lifetime Open-Market Net
$107.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKYO | Director | 35,201 | $1.64 | $57.7K | $25.0K | 3 | 2026-07-23 |
| Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Chairman | 7 | $0.08 | $1 | $10.7K | 6 | 2024-02-21 |
| CRDF | Director | 12,260 | $0.82 | $10.0K | $42.8K | 6 | 2022-06-09 |
| Cardiff Oncology, Inc. (TROV) Delisted | Director | 13,598 | — | — | $16.0K | 7 | 2019-06-24 |
| SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Director | 116,571 | — | — | $23.3K | 5 | 2018-07-06 |
| Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Director | — | — | — | $0 | 2 | 2018-07-03 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Director | — | — | — | $0 | 7 | 2017-01-05 |
| SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted | Director | 21,883 | — | — | -$14.5K | 11 | 2016-09-21 |
| ACEL | Director | 6,300 | $12.35 | $77.8K | $4.5K | 5 | 2009-01-05 |
| CALLISTO PHARMACEUTICALS INC (KAL) Delisted | Director | — | $1.12 | — | $0 | 1 | 2007-09-28 |
Recent Filings · Page 2 of 7
67 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-08-21 | Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-19 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2020-05-18 | CRDF | Buy (P) | +6,993 | $10.0K | EDGAR |
| 2020-04-07 | Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-25 | Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-24 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-06 | SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Mixed | +36,127 | $25.0K | EDGAR |
| 2018-07-03 | Hepion Pharmaceuticals, Inc. (CTRV) Delisted | Buy (P) | — | $0 | EDGAR |
| 2018-06-19 | SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-13 | Cardiff Oncology, Inc. (TROV) Delisted | Buy (P) | +10,000 | $8.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.